$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513304433 Filed on July 26, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$730.0K	$10.57M
YoY Change	-93.09%	-13.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.400M	$3.100M
YoY Change	9.68%	10.71%
% of Gross Profit
Research & Development	$10.53M	$8.818M
YoY Change	19.38%	7.85%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$13.90M	$11.95M
YoY Change	16.3%	8.03%
Operating Profit	-$13.17M	-$1.380M
YoY Change	854.13%	-225.91%
Interest Expense	$100.0K	$100.0K
YoY Change	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$925.0K	$879.0K
YoY Change	5.23%	-0.11%
Pretax Income	-$12.20M	-$500.0K
YoY Change	2340.0%	-125.0%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.24M	-$501.0K
YoY Change	2343.51%	-125.35%
Net Earnings / Revenue	-1676.99%	-4.74%
Basic Earnings Per Share	-$0.18	-$0.01
Diluted Earnings Per Share	-$0.18	-$0.01
COMMON SHARES
Basic Shares Outstanding	66.80M shares	66.31M shares
Diluted Shares Outstanding	66.80M shares	66.31M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.7M	$177.5M
YoY Change	-13.41%	54.08%
Cash & Equivalents	$44.31M	$42.02M
Short-Term Investments	$109.4M	$135.5M
Other Short-Term Assets	$2.119M	$2.179M
YoY Change	-2.75%	8.95%
Inventory
Prepaid Expenses
Receivables	$0.00	$1.500M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$155.9M	$181.3M
YoY Change	-14.02%	51.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.876M	$1.861M
YoY Change	0.81%	43.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.70M	$14.60M
YoY Change	-13.01%
Other Assets	$4.300M	$4.300M
YoY Change	0.0%	-29.51%
Total Long-Term Assets	$18.96M	$20.83M
YoY Change	-8.97%	181.47%
TOTAL ASSETS
Total Short-Term Assets	$155.9M	$181.3M
Total Long-Term Assets	$18.96M	$20.83M
Total Assets	$174.8M	$202.1M
YoY Change	-13.5%	58.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.348M	$1.420M
YoY Change	-5.07%	57.78%
Accrued Expenses	$8.185M	$6.937M
YoY Change	17.99%	-4.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.57M	$29.15M
YoY Change	-50.01%	-41.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$152.0K	$151.0K
YoY Change	0.66%	-99.71%
Total Long-Term Liabilities	$152.0K	$151.0K
YoY Change	0.66%	-99.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.57M	$29.15M
Total Long-Term Liabilities	$152.0K	$151.0K
Total Liabilities	$38.80M	$57.35M
YoY Change	-32.36%	-43.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$744.0M	-$726.1M
YoY Change	2.47%
Common Stock	$67.00K	$66.00K
YoY Change	1.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$136.0M	$144.7M
YoY Change
Total Liabilities & Shareholders Equity	$174.8M	$202.1M
YoY Change	-13.5%	58.62%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$12.24M	-$501.0K
YoY Change	2343.51%	-125.35%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%	-50.0%
Cash From Operating Activities	-$9.800M	-$6.900M
YoY Change	42.03%	16.95%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$200.0K
YoY Change	0.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$21.20M	-$27.90M
YoY Change	-175.99%	-9400.0%
Cash From Investing Activities	$21.00M	-$28.10M
YoY Change	-174.73%	-14150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.600M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-9.800M	-6.900M
Cash From Investing Activities	21.00M	-28.10M
Cash From Financing Activities	1.600M	0.000
Net Change In Cash	12.80M	-35.00M
YoY Change	-136.57%	525.0%
FREE CASH FLOW
Cash From Operating Activities	-$9.800M	-$6.900M
Capital Expenditures	-$200.0K	-$200.0K
Free Cash Flow	-$9.600M	-$6.700M
YoY Change	43.28%	15.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67062286	shares
CY2012Q1	nbix	Cease Use Liability CeaseUseLiability	2528000
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42018000
CY2012Q2	nbix	Cease Use Liability CeaseUseLiability	2463000
CY2013Q1	nbix	Cease Use Liability CeaseUseLiability	3492000
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66998103	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66998103	shares
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14573000
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-44000
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	879983000
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1348000
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	136016000
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-743990000
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1459000
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8185000
CY2013Q2	us-gaap	Liabilities Liabilities	38797000
CY2013Q2	nbix	Cease Use Liability Current CeaseUseLiabilityCurrent	402000
CY2013Q2	nbix	Deferred Gain On Sale Of Real Estate Noncurrent DeferredGainOnSaleOfRealEstateNoncurrent	19263000
CY2013Q2	nbix	Cease Use Liability CeaseUseLiability	3295000
CY2013Q2	nbix	Deferred Gain On Sale Of Real Estate Current DeferredGainOnSaleOfRealEstateCurrent	3179000
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2119000
CY2013Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	122132000
CY2013Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	38000
CY2013Q2	us-gaap	Long Term Investments LongTermInvestments	12749000
CY2013Q2	us-gaap	Assets Current AssetsCurrent	155853000
CY2013Q2	nbix	Cease Use Liability Noncurrent CeaseUseLiabilityNoncurrent	2893000
CY2013Q2	us-gaap	Deferred Gain On Sale Of Property DeferredGainOnSaleOfProperty	22400000
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1916000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	67000
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174813000
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	122176000
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4335000
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	68226000
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1876000
CY2013Q2	us-gaap	Assets Assets	174813000
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44313000
CY2013Q2	us-gaap	Short Term Investments ShortTermInvestments	109383000
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	68226000
CY2013Q2	nbix	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	25000
CY2013Q2	nbix	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	69000
CY2013Q2	nbix	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments	69000
CY2013Q2	nbix	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
CY2013Q2	nbix	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAccumulatedInInvestments	69000
CY2008Q4	us-gaap	Deferred Gain On Sale Of Property DeferredGainOnSaleOfProperty	39100000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50107000
CY2011Q4	nbix	Cease Use Liability CeaseUseLiability	2592000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66446888	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66446888	shares
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15646000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	873981000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	911000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	154372000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-719673000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2919000
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8094000
CY2012Q4	us-gaap	Liabilities Liabilities	41607000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1840000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	66000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195979000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	109741000
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4335000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	67492000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1900000
CY2012Q4	us-gaap	Assets Assets	195979000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63754000
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	109259000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	67492000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2162000
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	109739000
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	14089000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	480000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	189264000
CY2012Q4	nbix	Cease Use Liability Noncurrent CeaseUseLiabilityNoncurrent	3097000
CY2012Q4	nbix	Cease Use Liability Current CeaseUseLiabilityCurrent	589000
CY2012Q4	nbix	Deferred Gain On Sale Of Real Estate Noncurrent DeferredGainOnSaleOfRealEstateNoncurrent	20872000
CY2012Q4	nbix	Cease Use Liability CeaseUseLiability	3686000
CY2012Q4	nbix	Deferred Gain On Sale Of Real Estate Current DeferredGainOnSaleOfRealEstateCurrent	3133000
CY2012Q4	nbix	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	33000
CY2012Q4	nbix	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	35000
CY2012Q4	nbix	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments	35000
CY2012Q4	nbix	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
CY2012Q4	nbix	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLossesAccumulatedInInvestments	35000
	dei	Trading Symbol TradingSymbol	NBIX
	dei	Entity Registrant Name EntityRegistrantName	NEUROCRINE BIOSCIENCES INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000914475
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	800000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66700000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7948000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	323000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-32000
	us-gaap	Licenses Revenue LicensesRevenue	1460000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-42000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	95612000
	us-gaap	Investment Income Net InvestmentIncomeNet	224000
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1595000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-14094000
	us-gaap	Revenues Revenues	1460000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24359000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26142000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	32000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1825000
	us-gaap	Net Income Loss NetIncomeLoss	-24317000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1358000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	81819000
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	76000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6762000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2591000
	us-gaap	Share Based Compensation ShareBasedCompensation	3412000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	347000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19441000
	us-gaap	Operating Expenses OperatingExpenses	27602000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1460000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2591000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2600000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3400000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14084000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20840000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	528000
	nbix	Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount	2100000	shares
	nbix	Deferred Gain Recognized DeferredGainRecognized	1600000
	nbix	Lease Expiration Year LeaseExpirationYear	2019
	nbix	Deferred Gain On Sale Of Real Estate DeferredGainOnSaleOfRealEstate	1563000
	nbix	Share Based Compensation Arrangement By Share Based Payment Award Contractual Life ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualLife	P10Y
	nbix	Cease Use Liability Payment CeaseUseLiabilityPayment	391000
	nbix	Increase Decrease In Cease Use Liability IncreaseDecreaseInCeaseUseLiability	-391000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1400000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64857000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	25000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18082000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000	shares
CY2012Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-16000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2300000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2012Q2	us-gaap	Investment Income Net InvestmentIncomeNet	115000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	594000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-25000
	us-gaap	Licenses Revenue LicensesRevenue	18267000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-56000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	123161000
	us-gaap	Investment Income Net InvestmentIncomeNet	236000
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	1542000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	345000
	us-gaap	Revenues Revenues	21836000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1443000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3172000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	25000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1785000
	us-gaap	Net Income Loss NetIncomeLoss	-1387000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1490000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	50455000
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	159000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6802000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	83296000
	us-gaap	Share Based Compensation ShareBasedCompensation	2799000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	318000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8089000
	us-gaap	Operating Expenses OperatingExpenses	25008000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18266000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	83296000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	-28000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	26000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2800000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73303000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18206000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1205000
	nbix	Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount	1400000	shares
	nbix	Deferred Gain Recognized DeferredGainRecognized	1500000
	nbix	Deferred Gain On Sale Of Real Estate DeferredGainOnSaleOfRealEstate	1517000
	nbix	Sponsored Research And Development Revenue SponsoredResearchAndDevelopmentRevenue	3569000
	nbix	Cease Use Liability Payment CeaseUseLiabilityPayment	129000
	nbix	Increase Decrease In Cease Use Liability IncreaseDecreaseInCeaseUseLiability	-129000
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10900000	shares
CY2012Q1	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	8.10
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	83000000
CY2010Q4	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	600000
CY2010Q4	nbix	Subleased Agreement Area SubleasedAgreementArea	16000	sqft
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66309000	shares
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2400000	shares
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2012Q2	us-gaap	Licenses Revenue LicensesRevenue	9029000
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000
CY2010Q4	nbix	Sublease Term SubleaseTerm	P3Y
CY2012Q3	nbix	Subleased Agreement Area SubleasedAgreementArea	17000	sqft
CY2007	us-gaap	Sale Leaseback Transaction Lease Terms SaleLeasebackTransactionLeaseTerms	The Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.
CY2007	us-gaap	Proceeds From Sale Of Real Estate ProceedsFromSaleOfRealEstate	61000000
CY2007	nbix	Sale Leaseback Transaction Lease Period SaleLeasebackTransactionLeasePeriod	P12Y
CY2007	nbix	Property Plant Equipment Selling Price PropertyPlantEquipmentSellingPrice	109000000
CY2007	nbix	Mortgage Loans Assumed By Purchaser MortgageLoansAssumedByPurchaser	47700000
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	925000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-12242000
CY2012Q2	us-gaap	Revenues Revenues	10569000
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-517000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1380000
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	879000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-501000
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3131000
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	11949000
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1400000
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8818000
CY2012Q2	nbix	Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount	1300000	shares
CY2012Q2	nbix	Deferred Gain On Sale Of Real Estate DeferredGainOnSaleOfRealEstate	759000
CY2012Q2	nbix	Sponsored Research And Development Revenue SponsoredResearchAndDevelopmentRevenue	1540000
CY2012Q2	nbix	Cease Use Liability Payment CeaseUseLiabilityPayment	65000
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66799000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2013Q2	us-gaap	Licenses Revenue LicensesRevenue	730000
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	121000
CY2013Q2	us-gaap	Revenues Revenues	730000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12242000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13167000
CY2013Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	19000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3370000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	13897000
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1700000
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10527000
CY2013Q2	nbix	Potential Dilutive Securities That Could Be Included In Computation Of Earnings Per Share Amount PotentialDilutiveSecuritiesThatCouldBeIncludedInComputationOfEarningsPerShareAmount	2300000	shares
CY2013Q2	nbix	Deferred Gain On Sale Of Real Estate DeferredGainOnSaleOfRealEstate	781000
CY2013Q2	nbix	Cease Use Liability Payment CeaseUseLiabilityPayment	197000

Files In Submission

Name	View Source	Status
0001193125-13-304433-index-headers.html	Edgar Link	pending
0001193125-13-304433-index.html	Edgar Link	pending
0001193125-13-304433.txt	Edgar Link	pending
0001193125-13-304433-xbrl.zip	Edgar Link	pending
d551982d10q.htm	Edgar Link	pending
d551982dex101.htm	Edgar Link	pending
d551982dex102.htm	Edgar Link	pending
d551982dex311.htm	Edgar Link	pending
d551982dex312.htm	Edgar Link	pending
d551982dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nbix-20130630.xml	Edgar Link	completed
nbix-20130630.xsd	Edgar Link	pending
nbix-20130630_cal.xml	Edgar Link	unprocessable
nbix-20130630_def.xml	Edgar Link	unprocessable
nbix-20130630_lab.xml	Edgar Link	unprocessable
nbix-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2013 Q2 Form 10-Q Financial Statement

#000119312513304433 Filed on July 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2013 Q2 Form 10-Q Financial Statement

#000119312513304433 Filed on July 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix